OpportunityTitle: DoD Peer Reviewed Cancer Translational Team Science Award
Description: The Translational Team Science Award supports hypothesis-driven translational studies associated with an ongoing or completed clinical trial that could lead to a next-phase clinical trial or future clinical application. By leveraging information from ongoing or completed clinical trials, research projects funded by the TTSA should address critical knowledge gaps in outcomes, validate key research and expand upon potential transformative results, or investigate novel findings. Observations from ongoing or completed clinical trials may be utilized to formulate a new hypothesis to move to the next research stage or step of implementation of the clinical outcomes. The TTSA is not intended to fund the ongoing clinical trial. Applications associated with a clinical trial not yet started are discouraged. The TTSA may support preclinical studies in animal models and human subjects and human anatomical substances. Accordingly, development or use of relevant preclinical models may be included. The TTSA is not intended to support high-throughput screenings, sequencing, etc. Funding for clinical trials is not allowed. A clinical trial is defined as a prospective accrual of patients where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction. If a clinical trial is described in the context of the application package, it is incumbent upon the applicant to ensure that it is clear that the clinical trial associated with the proposed research will not be funded through this award mechanism. The Translational Team Science Award mechanism requires at least two, and up to three, Principal Investigators (PIs). One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as a Partnering PI(s). Initiating and Partnering PIs each have different submission requirements, as described in Section II; however, all PIs should contribute significantly to the development of the proposed research project. If recommended for funding, each PI will receive his or her own award. Applications should include clearly stated plans for interactions among all PIs and organizations involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. Important aspects of the Translational Team Science Award are as follows: Collaboration: The success of the project depends on the unique skills and contributions of each collaborator. At least two, and up to three, PIs must partner in one overarching study in at least one of the required FY16 PRCRP Topic Areas in Section I.B. At least one military or VA investigator is encouraged to be included as an equal partner in the research offering both intellectual investment and research effort. &#9675; A military or VA investigator is an investigator defined as active duty, active reserve, active duty detailed to agencies outside of the DoD, etc., or an investigator at a VA research facility. The military/VA investigator should have a substantial role in the research and should not be included only for access to active duty military and/or VA populations (see &#8216;Military Relevance&#8217; below). Translational Aspect: The application should provide evidence for the reciprocal transfer of information between basic and clinical science or vice-versa in developing and implementing the research plan. Translational research should include correlative studies based on completed or ongoing clinical trials (funding for the clinical trial is not allowed) or translational research. The application should demonstrate how the study will leverage information from ongoing or completed clinical trials to address knowledge gaps in resulting outcomes, validate key research and expand upon potential transformative results, or investigate novel findings. Military Relevance: The proposed research must address at least one of the FY16 PRCRP Military Relevance Focus Areas in Section I.C. The proposed research should be relevant to active duty Service members, their families, Veterans, and other military beneficiaries. Military relevance highlights the need to address exposures, conditions, or circumstances that are unique to the military or disproportionately represented within the military beneficiary population. Critical to the military health system is the expansion of knowledge in cancer research, patient care, and treatment options. Military relevance should be articulated with respect to the overall military health system, the VA, and the mission of the DHP. For more information, review the following websites: Military Health System (http://www.health.mil), Department of Veterans Affairs (http://www.va.gov/), the PRCRP (http://cdmrp.army.mil/prcrp/default.shtml), and the PRCRP Report to Congress (http://cdmrp.army.mil/prcrp/reports/reports.shtml). Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas (in prevention, diagnosis, detection, prognosis, treatment, and survivorship) in at least one of the FY16 PRCRP Topic Areas in Section I.B. into clinical applications. Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, or adaptations of existing methods or technologies. Preliminary Data Required: Data from an ongoing or completed clinical trial must be included in the application and/or citations of the investigators&#8217; work that are relevant to the proposed studies.
GrantorContactEmailDescription: CDMRP Help Desk
GrantorContactText: CDMRP Help Desk &lt;br/&gt;Phone: 301-682-5507 &lt;br/&gt;Email: help@eBRAP.org